Mammary Cell News Volume 5.40 | Oct 10 2013

Notch3 Marks Clonogenic Mammary Luminal Progenitor Cells In Vivo
Using a conditionally inducible Notch3-CreERT2SAT transgenic mouse, researchers genetically marked Notch3-expressing cells throughout mammary gland development and followed their lineage in vivo. [J Cell Biol] Abstract

IBP-Mediated Suppression of Autophagy Promotes Growth and Metastasis of Breast Cancer Cells via Activating mTORC2/Akt/FOXO3a Signaling Pathway
Investigators report that upregulation of interferon regulatory factor-4 binding protein (IBP) expression significantly suppressed the autophagy of breast cancer cells, and downregulation of IBP expression markedly induced autophagy of these cells. [Cell Death Dis] Full Article

mTORC1/2 Targeted by n-3 Polyunsaturated Fatty Acids in the Prevention of Mammary Tumorigenesis and Tumor Progression
Four complementary and well-controlled animal models were utilized to identify the role and molecular target of n-3 polyunsaturated fatty acids in the prevention of breast carcinogenesis and progression. [Oncogene] Abstract

Signaling Events Mediated by α3β1 Integrin Are Essential for Mammary Tumorigenesis
Researchers showed that the deletion of α3β1 integrin, a major laminin receptor, from the basal layer of the mammary epithelium of K5ΔNβcat mice completely prevented the tumorigenesis induced by β-catenin signaling. [Oncogene] Abstract

Tumor Microenvironmental Signaling Elicits Epithelial-Mesenchymal Plasticity through Cooperation with Transforming Genetic Events
Investigators explore how extrinsic, tumor microenvironmental cytokines cooperate with intrinsic, genetic changes to promote epithelial-to-mesenchymal transition in human mammary epithelial cells. [Neoplasia]
Full Article

AMG 900, Pan-Aurora Kinase Inhibitor, Preferentially Inhibits the Proliferation of Breast Cancer Cell Lines with Dysfunctional p53
Researchers evaluated the in vitro activity of AMG 900 in a panel of 44 human breast cancer and immortalized cell lines and identify predictors of response. [Breast Cancer Res Treat] Abstract

Non-Overlapping Activities of ADF and Cofilin-1 During the Migration of Metastatic Breast Tumor Cells
Scientists investigated the roles of Actin Depolymerizing Factor (ADF) and cofilin-1 individually in the development of polarized migration of rat mammary adenocarcinoma cells. [BMC Cell Biol]
Abstract | Full Article

CLINICAL RESEARCH

A Phase II Study of Everolimus Combined with Trastuzumab and Paclitaxel in Patients with HER2-Overexpressing Advanced Breast Cancer that Progressed During Prior Trastuzumab and Taxane Therapy
In this phase II multicenter study, adult patients with HER2-positive advanced breast cancer resistant to trastuzumab and pretreated with a taxane received everolimus 10 mg/day in combination with paclitaxel (80 mg/m2 days 1, 8, and 15 every 4 weeks) and trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly), administered in 28-day cycles. [Breast Cancer Res Treat] Full Article

Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer
In this phase II multicenter trial, nab-paclitaxel and carboplatin were administered weekly with biweekly bevacizumab to 34 patients with first-line triple negative metastatic breast cancer. [Clin Breast Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Rutgers Cancer Institute of New Jersey Researchers Awarded Nearly $2.5M to Examine Ways to Block Cancer Cell Growth
X.F. Steven Zheng, PhD was awarded a five-year $1.65 million grant from the National Institutes of Health (NIH) to examine an activating mechanism of the mTOR protein, which is a central controller of cell growth and metabolism. Darren R. Carpizo, MD, PhD, FACS was awarded a five-year grant from the NIH totaling $794,790. The funding will be utilized to further explore the effects of a compound identified in Dr. Carpizo’s laboratory that is found to restore tumor suppressor function of a mutated p53 gene in cancer cells. [Rutgers Cancer Institute of New Jersey] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Postdoctoral Position – Breast Cancer Research (Albert Einstein College of Medicine)

NEW Postdoctoral Position – Computational Biology and Cancer Genomics (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology of Cancer (Gustave Roussy Cancer Institute)

Postdoctoral Position – Triple Negative Breast Cancer (Weizmann Institute of Science)

Postdoctoral Fellow – Nutritional Cancer Epigenetics (Purdue University)

PhD Position – Breast Cancer Bone Metastasis Formation (Claude Bernard University Lyon 1)

Faculty Position – Management/Research of Hematologic, Breast, Head and Neck, Gastrointestinal, and Thoracic Medicine (Vanderbilt University Medical Center)

Vice President, Global Medical Affairs Position – Breast Disease (Celgene Corporation)

Postdoctoral Fellow – Breast Cancer Biology (Stephenson Cancer Center at the University of Oklahoma)

Research Assistant – Cellular Pathways Involved in Oncogenic Transformation of Breast Epithelial Cells (Mount Sinai School of Medicine)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.